Efficacy and safety of PD‑1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study-Reference-Cited by-同舟云学术

Efficacy and safety of PD‑1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study

Published:2023-05-31 Issue:1 Volume:26 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Wu Zhiheng¹,Zhu Xudong²,Zhong Xian³,Wang Yiran¹,Zheng Yu⁴,Han Weidong⁴,Pan Hongming⁴,Yao Junlin⁴

Affiliation:

1. Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China

2. Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China

3. Department of Medical Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China

4. Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Reference26 articles.

1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

2. Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials;Eckel;Br J Cancer,2007

3. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC;Chu;J Thorac Oncol,2021

4. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial;Yau;Lancet Oncol,2022

5. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma;Mao;J Cancer,2021